AbbVie Inc. (ABBV)
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
AbbVie NYSE: ABBV spooked the market in early October, but the sell-off is a buying opportunity. The critical takeaway is that only the earnings guidance was altered; the trim was small and offset by the cause.
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Undervalued Dividend Kings: October 2024
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway.
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
Declining earnings haven't scared billionaire investors away from this stock.
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
These companies can lend growth and dividend returns to a long-term investor's portfolio.
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
AbbVie (ABBV) closed the most recent trading day at $195.45, moving -0.7% from the previous trading session.
AbbVie cuts 2024 profit forecast on R&D expenses
AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing $82 million in milestones, and research and development expenses related to acquisitions.
AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia
AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine and Tavapadon show strong clinical trial results, positioning them as potential best-in-class treatments for Schizophrenia and Parkinson's Disease, respectively. AbbVie demonstrates financial strength with rising revenues from Skyrizi and Rinvoq, supporting a bullish long-term investment thesis despite Humira's decline.
3 Top Pharma Stocks to Buy in October 2024
The pharmaceutical industry plays a crucial role in most of our everyday lives.
